Filing Details
- Accession Number:
- 0001209191-21-014690
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-26 16:07:07
- Reporting Period:
- 2021-02-24
- Accepted Time:
- 2021-02-26 16:07:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-02-24 | 2,898 | $217.57 | 44,737 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2021-02-25 | 380 | $211.39 | 44,357 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-25 | 900 | $212.52 | 43,457 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-25 | 1,400 | $213.55 | 42,057 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-25 | 400 | $214.32 | 41,657 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-25 | 300 | $215.62 | 41,357 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-25 | 254 | $216.57 | 41,103 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $211.39 (range $210.76 to $211.68).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $212.52 (range $212.05 to $213.02).
- Open market sales reported on this line occurred at a weighted average price of $213.55 (range $213.09 to $214.08).
- Open market sales reported on this line occurred at a weighted average price of $214.32 (range $214.10 to $214.62).
- Open market sales reported on this line occurred at a weighted average price of $215.62 (range $215.37 to $215.84).
- Open market sales reported on this line occurred at a weighted average price of $216.57 (range $216.50 to $216.62).
Billionaire Hedge Funds
